ProCE Banner Events


Ensuring Optimal Clinical Benefit From Oral SERD Therapy in Patients With HR+/HER2- Breast Cancer

Join us for an interactive webinar featuring expert recommendations on managing HR-positive/HER2-negative metastatic breast cancer, including up-to-date efficacy and safety data on approved and emerging oral SERDs. Engaging discussions on adverse event management and promoting adherence and treatment persistence with oral anticancer therapies will be facilitated using standardized patient simulation videos.

Registered Nurses: 1.50 Nursing contact hours

Physician Assistants/Physician Associates: 1.50 AAPA Category 1 CME credits

Who Should Attend

This program is intended for oncology physician associates/nurse practitioners, oncology nurses, and other healthcare professionals who care for patients with breast cancer. 

Time and location

Saturday, February 24, 2024

10:00 AM - 11:30 AM Eastern Time (ET)


Jamie Carroll, MSN, CNP, APRN

Assistant Professor in Medical Oncology
Mayo Clinic
Rochester, Minnesota

Manali Bhave, MD

Phase I Medical Director
Assistant Professor
Department of Hematology & Medical Oncology
Winship Cancer Institute
Emory University
Atlanta, Georgia


Overview and Baseline Assessment

Current Management of Progressive HR-Positive/HER2-Negative Metastatic Breast Cancer

  • Strategies and indications for continuing CDK4/6 inhibition
  • Options after CDK4/6 inhibitor–based therapy
  • Expanding evidence base for oral SERDs and other ER-targeting agents

Recognition and Management of Adverse Events

Promoting Adherence to Oral Anticancer Therapies

Prevention of Early Discontinuation of Oral Anticancer Therapies

Question and Answer Session


Goal Statement
The goal of this program is to improve the knowledge, competence, and performance of learners to optimize clinical benefit by maintaining adherence and persistence with oral SERDs in the treatment of patients with HR+/HER2- breast cancer. 

Target Audience
This program is intended for oncology physician associates/nurse practitioners, oncology nurses, and other healthcare professionals who care for patients with breast cancer. 

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Plan treatment for patients with HR+/HER2- MBC progressing on first line endocrine therapy with or without CDK4/6 inhibitor based on individual patient and disease characteristics, genomic profile, available clinical data, new approvals, and expert recommendations
  • Mitigate and manage toxicities associated with oral SERD therapy for patients with HR+/HER2- breast cancer
  • Implement recommended strategies to improve adherence to oral SERD therapy in patients with HR+/HER2- breast cancer
  • Employ effective techniques to address factors leading to early discontinuation of oral anticancer therapy for the prescribed duration of treatment in patients with HR+/HER2- breast cancer


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.5 contact hours.

Physician Associate Continuing Medical Education

Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. PAs should only claim commensurate with the extent of their participation.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.


Provided by Clinical Care Options, LLC, in partnership with Practicing Clinicians Exchange and ProCE, LLC.

This activity is supported by an educational grant from Lilly.

Contact Information

For customer support please click here.

Mailing Address:


Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Additional Information

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact customer support prior to the live event.